Clinical trials
catalyst calendar across sponsors →Studies where CMPX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 1 with posted results
Held by 13 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, Qube Research & Technologies Ltd, CITADEL ADVISORS LLC, AQR CAPITAL MANAGEMENT LLC, Squarepoint Ops LLC, +8 more) · FINRA short interest 17.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine NeoplasmsNCT07684170Evaluate the clinical activity of CTX-471Randomized · Open-label · Treatment | Phase 2 | Not yet recruiting | Drug: CTX-471 | Neuroendocrine Neoplasm, Neuroendocrine Carcinomas, Neuroendocrine Tumors | 58 | Sep 2028 | ≤ 773 d | 2026-07-06 |
| A Phase 1 Study of the Safety and Tolerability of CTX-10726NCT07419841Cohort 1: Evaluate the safety and tolerability of CTX-10726 by incidence of treatment-emergent adverse events (TEAEs) in escalating dosesNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: CTX-10726 | Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC) | 70 | 2028-04-01 | in 591 d | 2026-07-31 |
| A Phase 1 of CTX-8371 in Patients With Advanced MalignanciesNCT06150664Cohort 1: Evaluate the safety and tolerability of escalating doses of CTX-8371Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: CTX-8371 | Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma | 85 | Dec 2026 | ≤ 134 d | 2026-07-28 |
| A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)NCT05506943Best Overall ResponseRandomized · Single-masked · Treatment | Phase 2/3 | Active, not recruiting | Drug: CTX-009, Paclitaxel | Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer | 168 | 2026-12-01 | in 104 d | 2026-05-07 |
| Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced MalignanciesNCT03881488Number of participants with dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalitiesNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: CTX-471, Pembrolizumab (KEYTRUDA®) | Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Melanoma, Head and Neck Cancer | 100 | 2025-05-21actual | — | 2026-04-17 |
| A Study of CTX-009 in Adult Patients With Metastatic Colorectal CancerNCT05513742results2026-07-28Overall Response RateOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: CTX-009 | Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer | 49 | 2025-05-15actual | — | 2026-07-28 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19